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Introduction
The fibrinolytic system is essential in the maintenance
of blood vessel patency and removal of extravascular
fibrin deposition. It is also thought to play a critical
role in the degradation of extracellular matrices in con-
cert with other proteinases in a number of physiologi-
cal and pathological conditions (1–5). Plasmin is the
key protease in the fibrinolytic system that degrades
fibrin. It is converted from a circulating zymogen, plas-
minogen, by either tissue-type plasminogen activator
(t-PA) or urokinase-type plasminogen activator (u-PA).
Inhibition of the fibrinolytic system may occur at the
level of plasmin by α2-antiplasmin or at the level of its
activators by plasminogen activator inhibitors, pre-
dominantly PAI-1. Recently, another protein, throm-
bin-activatable fibrinolysis inhibitor, has been shown
to inhibit the fibrinolytic system.
Thrombin-activatable fibrinolysis inhibitor (TAFI;
EC 3.4.17.20) is a 60-kDa plasma glycoprotein that pos-
sesses carboxypeptidase B activity upon activation. This
glycoprotein was originally described as a novel basic
carboxypeptidase generated in serum following coagu-
lation, which was distinct from carboxypeptidase N
(EC 3.4.17.3), the key plasma enzyme responsible for
degradation of anaphylatoxins (6, 7). Because of its
instability, Hendriks et al. named it carboxypeptidase
U (U referring to unstable; ref. 6), while Campbell et al.
named it arginine carboxypeptidase (carboxypeptidase
R; ref. 7). Meanwhile, a novel protein with a high affin-
ity for plasminogen was isolated, cloned, and shown to
have high-sequence homology to that of pancreatic
procarboxypeptidase B (8). Following incubation with
a serine protease such as trypsin or thrombin, this pro-
tein had carboxypeptidase B activity and was termed
plasma procarboxypeptidase B. Subsequent character-
ization revealed the identity between carboxypeptidase
U and plasma procarboxypeptidase B (9). The same
protein was purified and characterized by Bazjar et al.,
who demonstrated that this protein inhibited fibrinol-
ysis following its activation by thrombin, hence the
name “thrombin-activatable fibrinolysis inhibitor” (10,
11). The potential role of this enzyme in the regulation
of fibrinolysis was also suggested based on other in
vitro and in vivo studies (9, 12–16).
In vitro TAFI is activated via proteolytic cleavage of a
92 amino acid–long activation peptide by a high con-
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To investigate the consequence of deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI),
we generated homozygous TAFI-deficient mice by targeted gene disruption. Intercrossing of 
heterozygous TAFI mice produced offspring in the expected Mendelian ratio, indicating that trans-
mission of the mutant TAFI allele did not lead to embryonic lethality. TAFI-deficient mice developed
normally, reached adulthood, and were fertile. No gross physical abnormalities were observed up to
24 months of age. Hematological analysis of TAFI-deficient mice did not show any major differences
including plasma fibrinogen level, prothrombin time, and activated partial thromboplastin time.
TAFI-deficient mice did not suffer from excess bleeding as determined by blood loss following tail
transection, although their plasma failed to prolong clot lysis time in vitro. In vivo, TAFI deficiency
did not influence occlusion time in either an arterial or a venous injury model. TAFI deficiency did
not improve survival rate compared with the wild-type in thrombin-induced thromboembolism, fac-
tor X coagulant protein–induced thrombosis, and endotoxin-induced disseminated intravascular
coagulation. Furthermore, TAFI deficiency did not alter kaolin-induced writhing response, imply-
ing that TAFI does not play a major role in bradykinin catabolism. The current study demonstrates
that TAFI deficiency does not change normal responses to acute challenges.
J. Clin. Invest. 109:101–110 (2002). DOI:10.1172/JCI200212119.
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centration of trypsin, thrombin, or plasmin to a zinc
metalloprotease (8–12). The activation of TAFI by
thrombin is greatly enhanced in the presence of
thrombomodulin (11, 14, 16). In vitro activated TAFI
(TAFIa) can cleave C-terminal basic residues from var-
ious natural and synthetic peptides, including biologi-
cally active peptides such as bradykinin and anaphyla-
toxins (12, 17, 18). However, partially degraded fibrin
is likely to be a physiological substrate of TAFIa. The
newly exposed C-terminal lysine residues of fibrin fol-
lowing partial degradation by plasmin bind both plas-
minogen and t-PA with high affinity, thereby potenti-
ating plasmin generation at the surface of fibrin clot
(19–22). Activation of TAFI during clot lysis results in
removal of these C-terminal lysines, and consequently,
reduced plasmin production, leading to a several-fold
prolongation of clot lysis time. Numerous in vivo stud-
ies in the rabbit have demonstrated that inhibition of
TAFI activity with carboxypeptidase inhibitor from
potato (CPI) enhanced t-PA–induced thrombolysis as
well as endogenous fibrinolysis (23–26). Furthermore,
fibrin deposition in either the lung or kidney of the rat
in response to endotoxin was reduced by inhibition of
TAFI activity (27, 28). Therefore, accumulating evi-
dence indicates that TAFI plays a role in the regulation
of fibrinolysis in vivo with a caveat that in these stud-
ies CPI was used to preferentially block TAFI activity.
While it is inactive against carboxypeptidase N, it
inhibits a number of other carboxypeptidases present
in the body (for review, see ref. 29).
Mouse models deficient in each component of the
fibrinolytic system have been generated to examine
their role in development, thrombosis, thrombolysis,
reproduction, wound repair, and cell migration
(30–34). Unlike deficiency in coagulation factors such
as tissue factor or factor V, which are embryonic lethal,
deficiency in a component of the fibrinolytic system
results in animals that develop normally with no obvi-
ous phenotypic abnormalities. However, plasminogen-
deficient mice suffered spontaneous thrombosis, and
wound healing was grossly impaired (32, 33). Further-
more, plasminogen activator–deficient mice had
impaired lysis of microthrombi in the lung and
increased fibrin deposition in response to endotoxin
challenge (31), while mice deficient in either PAI-1 or
α2-antiplasmin had increased thrombolysis and were
more resistant to endotoxin-induced thrombosis (30,
34). To examine the consequence of TAFI deficiency on
endogenous fibrinolysis, as well as other prothrom-
botic challenges, we generated homozygous TAFI-defi-
cient mice by targeted gene disruption. Such an animal
model can also be used to determine if TAFI is involved
in the turnover of biologically active peptides possess-
ing C-terminal basic residues. Here we report the gen-
eration and characterization of TAFI-deficient mice.
Methods
Animals. All mice were maintained in an animal facility
accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
The protocols for in vivo studies were approved by Berlex
Biosciences Animal Care and Use Committee. Mice were
in a mixed background of C57BL/6 and 129/Sv and used
at an age between 8 and 12 weeks old. For most of the
studies, wild-type littermates were used as controls.
However, for tail bleeding, thrombin-induced pul-
monary thromboembolism, and LPS-induced dissemi-
nated intravascular coagulation studies in which large
numbers of mice were required, offspring of TAFI-defi-
cient mice used for breeding were compared with off-
spring of their wild-type littermates used for breeding.
Materials. Human thrombin (3,000 NIH U/mg,
obtained by a direct comparison to an NIH thrombin
reference standard; 1 NIH unit equals 1.15 IU) was pur-
chased from American Diagnostica Inc. (Greenwich,
Connecticut, USA). Recombinant tissue-type plas-
minogen activator (580,000 IU/mg) was purchased
from Genentech Inc. (South San Francisco, California,
USA). Human thrombomodulin was purified as
described previously (35). Endotoxin (Escherichia coli
LPS, serotype 0111:B4), HEPES, and 3-[(3-cholamido-
propyl)dimethylammonio]-1-propane-sulfonate
(CHAPS) were obtained from Sigma Chemical Co. (St.
Louis, Missouri, USA). Furylacryloyl-alanyl-arginine
(FA-Ala-Arg) was from Bachem AG (Bubendorf,
Switzerland). D-Phe-Pro-Arg chloromethylketone
(PPACK) and D-Val-Phe-Lys chloromethylketone were
obtained from Calbiochem-Novabiochem Corp. (San
Diego, California, USA). Lovenox (enoxaparin sodium)
was purchased from Aventis Pharmaceuticals Inc.
(Bridgewater, New Jersey, USA).
Generation of TAFI gene-disrupted mice. The full-length
murine TAFI cDNA was isolated from a mouse liver
cDNA library (lambda ZAP; Stratagene, La Jolla, Cali-
fornia, USA) using a partial human TAFI cDNA as
probe. The murine TAFI cDNA was used to screen a P1
genomic library prepared from the genomic DNA iso-
lated from the 129/Sv mouse (Genome Systems Inc., St.
Louis, Missouri, USA). A 9.2-kb SacI fragment of TAFI
DNA containing exons 6 to 9 and a 6.4-kb SpeI DNA
fragment containing exon 10 were subcloned into
pBluescript II KS (Stratagene) producing plasmids A
and B, respectively. For the construction of the target-
ing vector, a HSV-thymidine kinase (tk) cassette was
placed at the KpnI site within the multiple cloning site
of pBluescript II KS using blunt-end ligation. A 0.9-kb
AccI-HindIII TAFI DNA fragment spanning a portion
of intron 7 and half of exon 8 from plasmid A was sub-
cloned into pET-21b (Stratagene) at its multiple cloning
site. A XhoI-HindIII fragment containing the TAFI
DNA was removed from the resulting pET-21b plasmid
and was inserted between XhoI and HindIII sites direct-
ly after the tk cassette in the targeting vector. A SalI
fragment containing a 1.5-kb PGK-neomycin phospho-
transferase (neo) cassette was inserted into plasmid B
directly upstream of the 6.4-kb TAFI DNA. Construc-
tion of the targeting vector was then completed by
inserting a 7.9-kb XhoI-NotI DNA fragment from plas-
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mid B, containing the neo cassette and exon 10 of TAFI
gene, between SalI and NotI sites of the targeting vector
(Figure 1a). The targeting vector was linearized with
NotI and introduced by electroporation into 129/Sv-
derived R1 embryonic stem cells (gift from A. Nagy, Uni-
versity of Toronto, Ontario, Canada), and stable trans-
fectants were selected as described previously (36). Of
420 clones, two contained the expected allele as deter-
mined by Southern blot analysis. An embryonic stem
cell clone was injected into C57BL/6 blastocysts as
described (36), and the resulting male chimeras were
bred to C57BL/6 females to generate heterozygous F1
offspring. Heterozygous TAFI mice were intercrossed,
yielding TAFI+/+, TAFI+/–, and TAFI–/– F2 littermates.
Genotypic analysis. Genomic DNA was isolated from
either tail clips or ear biopsies and used for genotyping by
either Southern blot analysis or PCR analysis. For South-
ern blotting, a 0.45-kb HindIII fragment of TAFI genom-
ic DNA encompassing exon 6 was used as a hybridization
probe. PCR analysis of the TAFI gene was performed
using three primers derived from (a) the upstream por-
tion of exon 8 (5′-AGAAAGGTGCGTCAAGTTCCTCC-3′), (b)
a portion of exon 8 deleted in the mutant allele (5′-
GTTCTTCGTGGTCCTTGCTTTTG-3′), and (c) the neo cas-
sette (5′-TTCCTGACTAGGGGAGGAGTAGAAG-3′). The
PCR product derived from the wild-type allele is 190 bp,
and that derived from the mutant allele is 390 bp.
RT-PCR. mRNA was extracted from mouse liver using
a FastTrack 2.0 kit (Invitrogen Corp., Carlsbad, Cali-
fornia, USA) according to the manufacturer’s instruc-
tions. First-strand cDNA was synthesized by oligo (dT)
priming using the First-Strand cDNA Synthesis kit
(Roche Molecular Biochemicals, Indianapolis, Indiana,
USA). The first-strand cDNA product was used in the
subsequent PCR amplification with primers, one
annealing to the 5′ end of TAFI cDNA (5′-CAAGT-
CACTGTTGGGATGAAGC-3′) and the second one anneal-
ing to the 3′ end of TAFI cDNA (5′-ATTAACTGTTCCT-
GATGACATGCC-3′). All the PCR products were analyzed
by electrophoresis on 1% agarose gels.
Determination of TAFI antigen in plasma. The presence
of TAFI in plasma was demonstrated using either West-
ern blot analysis or an ELISA. Mouse platelet-poor plas-
ma was obtained by centrifugation of citrated blood
(9:1 vol/vol with 3.8% sodium citrate) at 1,500 g for 15
minutes. For Western blot analysis, plasma was diluted
fivefold with 0.1 M NaCl, 1 mM EDTA, 0.05 M Tris-
HCl, pH 7.5, and 10 µl samples were separated by 10%
SDS-PAGE. Western blot analysis was performed as
described previously using rabbit Ab’s raised against a
peptide representing residues 155–167 (CGI-
HAREWISPAF) of mature TAFI (36, 37). The TAFI
ELISA was performed using a commercial kit designed
for detection of human TAFI (Enzyme Research Labo-
ratories, South Bend, Indiana, USA), with purified
human TAFI as a standard, according to the manufac-
turer’s instructions without any modifications.
Determination of TAFIa and carboxypeptidase N activity in
plasma. To measure TAFIa activity, 75 µl plasma was
diluted with 25 µl of water and allowed to clot at room
temperature with addition of thrombin (4.5 NIH U/ml,
final), thrombomodulin (50 nM, final), and calcium
chloride (17 mM, final). Ten minutes later, the clot was
squeezed and discarded, and activation of TAFI was ter-
minated by addition of PPACK (1 µM, final). Total car-
boxypeptidase B activity (TAFIa and carboxypeptidase
N activity) was measured by addition of a 40-µl aliquot
of the remaining fluid to 960 µl of 0.02 M Tris-HCl, pH
7.8, 0.075 M NaCl, and 0.1% (wt/vol) CHAPS contain-
ing FA-Ala-Arg (0.4 mM final) as a substrate. The rate of
hydrolysis of FA-Ala-Arg was determined by measuring
changes in absorbance at 336 nm every 20 seconds for
10 minutes. Carboxypeptidase N (CPN) activity was
measured similarly in the diluted plasma without addi-
tion of thrombin and thrombomodulin. The values for
CPN thus obtained were same as those obtained by
measuring the total carboxypeptidase B activity as
described above, except in the presence of CPI.
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Figure 1
TAFI gene-disruption in mice. (a) TAFI replacement construct and
partial restriction map of the endogenous locus. Exon 8 and 9
encodes some of the zinc and substrate binding sites of TAFI. (b)
Southern blot analysis of TAFI gene disruption. The probe indicated
in a was used to detect 9.2-kb DNA fragment in the wild-type allele
and 7.0-kb DNA fragment in the mutant allele following Sac1 diges-
tion of genomic DNA. (c) Western blot analysis of plasma TAFI from
the wild-type, heterozygous, and homozygous TAFI mice. Ab raised
against TAFI peptide (CGIHAREWISPAF) hybridized to a band with
a molecular weight similar to that of murine albumin only in the plas-
ma from the wild-type and heterozygous mice. (d) RT-PCR analysis
of liver mRNA isolated from TAFI+/+, TAFI+/–, and TAFI–/– mice. RT-PCR
products obtained with primers that span the entire coding region
of TAFI cDNA in the presence of reverse transcriptase (RT) are shown
on the left-hand side and those in the absence of reverse transcrip-
tase are on the right-hand side. Neo, neomycin phosphotransferase
gene; tk, thymidine kinase gene; probe, TAFI-specific probe used in
Southern blot analysis (which encodes exon 6). 
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In vitro plasma clot lysis. The clot lysis profile of mouse
plasma was determined using a 96-well microtiter plate
clot lysis assay. Fifteen microliters of citrated plasma
was mixed with 3 µl of 2 µM thrombomodulin and 60
µl of 0.04 M HEPES, pH 7.0, 0.15 M NaCl, and 0.01%
Tween 80 (vol/vol). The mixture was immediately
added to another well containing 4 µl of 75 NIH U/ml
thrombin, 2 µl of 1 M CaCl2, and 4 µl of 0.5 µg/ml t-PA
in separate aliquots. The total volume of the mixture
was made up to 120 µl with water. After mixing, the
change in absorbance at 405 nm was monitored at
37°C every minute for 60 minutes using a SpectraMAX
250 Microplate Spectrophotometer (Molecular Device
Corp., Sunnyvale, California, USA). Lysis time was
defined as the time at which the absorbance is one-half
of the difference between the plateau reached after clot-
ting and the base line value achieved at complete lysis.
Hematological analysis, coagulation assays, and tail bleeding.
Blood samples were collected from the inferior vena
cava of animals into one-tenth volume of 3.8% sodium
citrate. Blood cell counts were analyzed using a Baker
9120+CP Cell Counter (ABX Diagnostics Inc., Irvine,
California, USA). Fibrinogen level was determined
according to the method described by Macart (38), and
the results are expressed as a percentage of the initial
value. The activated partial thromboplastin time (aPTT)
and prothrombin time (PT) were performed with
platelet-poor plasma using an Electra 900C coagu-
lometer (Beckman Coulter, Brea, California, USA). For
blood chemistry analysis, serum was obtained from
clotted whole blood and analyzed by IDEXX Veterinary
Services Inc. (West Sacramento, California, USA). For
measurement of tail bleeding, mice were anaesthetized
with an intraperitoneal injection of pentobarbital (62.5
mg/kg body weight), and a 1-mm segment was ampu-
tated from the tip using a device that cuts with a razor
blade. The tail was immediately immersed in 25 ml of
saline prewarmed to 37°C, with constant mixing. After
30 minutes, 5 ml of 5% EDTA in PBS was added, and the
number of red blood cells released from the tail wound
into saline was determined with a Baker 9120+CP Cell
Counter. For studying the effect of heparin on tail
bleeding, mice were preinjected in the tail vein with
Lovenox, a low-molecular-weight heparin (3 mg/kg
body weight) 2 minutes before tail amputation.
Mouse thrombosis models. A murine model of vascular
injury induced by a photochemical reaction either in
the artery or in the vein was per-
formed as described previously
(39). Briefly, either the left com-
mon carotid artery or the left
jugular vein was isolated, and a
vascular flow probe (Transonic
Systems, Ithaca, New York,
USA) was applied to monitor
blood flow continuously. Rose
bengal (Fisher Scientific Co.,
Pittsburgh, Pennsylvania, USA)
at a concentration of 10 mg/ml
in PBS was injected into the tail vein to administer a
dose of 50 mg/kg. A mid portion of either the common
carotid artery or the jugular vein was illuminated with
a 1.5-mW green light laser (540 nm; Melles Griot Inc.,
Irvine, California, USA) until an occlusive thrombus
was formed. The time required to form the occlusive
thrombus, defined as no detectable flow for 1.0 minute
or more, was recorded. The operator was blinded to the
genotype of mouse during the experiment.
In the thrombin-induced acute thromboembolism
model, human thrombin was injected over 2 to 3 sec-
onds into the tail vein of conscious mice at a dose of
1,600, 2,400, or 3,200 NIH U/kg body weight. The sur-
vival rate at 10 minutes after intravenous administration
of thrombin was measured as an index of the severity of
thromboembolism. In the endotoxin-induced septic
shock model, mice were injected intraperitoneally with
either 30 mg/kg or 40 mg/kg body weight of LPS dis-
solved in saline. The mice were observed for signs of
endotoxemia daily, such as lethargy, scruffy fur, and
some exudate from eyes, and survival time was recorded.
In separate experiments, an effect of LPS on fibrin dep-
osition in the kidney was investigated. Three hours after
injection of LPS, mice were anesthetized and citrated
blood was collected by cardiac puncture. Kidneys were
perfused immediately with PBS containing 3.8% sodium
citrate, 100 µg/ml Lovenox, and 1 µM D-Val-Phe-Lys
chloromethylketone, followed by 4% paraformaldehyde
(in PBS, sucrose 1% wt/vol). The kidneys were harvested
and fixed overnight with fresh 4% paraformaldehyde.
Kidneys were cut in half and embedded in paraffin. Tis-
sue sections (5 µM-thickness) were cut, hydrated, and
incubated sequentially first with a solution of 3% hydro-
gen peroxide in PBS for 30 minutes and then a 10% nor-
mal goat serum in PBS at room temperature. Sections
were immunostained for fibrin/fibrinogen using a rab-
bit antifibrinogen antiserum (kindly provided by J.L.
Degen; University of Cincinnati, Ohio, USA; diluted
1:1000, vol/vol) followed by biotinylated goat anti-rab-
bit IgG, and detected with streptavidin peroxidase con-
jugate and diaminobenzidine (Zymed Laboratories, Inc.,
South San Francisco, California, USA). Following
immunostaining, the extent of fibrin deposition was
analyzed by a pathologist without prior knowledge of
the genotype of the mice. In the factor X coagulant 
protein–induced (XCP-induced) subacute thrombosis
model, mice were injected intraperitoneally with 
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Table 1
Plasma TAFI antigen and carboxypeptidases activities 
TAFI+/+ TAFI+/– TAFI–/–
TAFI antigen (nM, equivalent) 0.62 ± 0.23 (n = 5) 0.34 ± 0.12 (n = 6) 0.07 ± 0.03 (n = 7)
TAFIa activity (mOD/min) 0.88 ± 0.33 (n = 5) 0.52 ± 0.29 (n = 6) 0.1 ± 0.15 (n = 7)
CPN activity (mOD/min) 3.72 ± 1.18 (n = 5) 3.63 ± 0.67 (n = 6) 4.7 ± 1.06 (n = 7)
TAFI antigen level in plasma was measured using an ELISA assay kit with purified human TAFI as a standard.
TAFI activity in plasma was determined using FA-Ala-Arg as substrate following its activation with throm-
bin (4.5 NIH U/ml), thrombomodulin (50 nM), and CaCl2 (17 mM) as described in Methods. CPN activi-
ty was determined similarly without addition of thrombin, thrombomodulin, and CaCl2. The number of
mice used in each group is indicated in parentheses. mOD, milli-optical density.
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150 µg/kg body weight XCP from Russell viper venom.
The survival rate, platelet counts, and fibrinogen level
were determined at 2 and 16 hours.
Kaolin writhing test. Mice were injected intraperi-
toneally with 0.5 ml kaolin suspended in saline (5
mg/ml) to introduce the writhing stretching response
(40, 41). Subsequent writhing responses were counted
over the next 15 minutes.
Statistical analysis. All data are presented as mean
plus or minus SEM. The significance of differences in
tail bleeding between groups was determined by
ANOVA. For occlusion time, the nonparametric
Kruskal-Wallis one-way ANOVA followed by the
Mann-Whitney U test was used. P values less than
0.05 were considered significant.
Results
Generation of TAFI-deficient mice. To investigate in vivo
consequences of TAFI deficiency, the TAFI gene was
disrupted in mice as described in Methods. Successful
gene targeting resulted in the replacement of a portion
of exon 8 and 9 with a neo cassette (Figure 1a), there-
by removing the DNA segment encoding residues crit-
ical for substrate and zinc binding essential for cat-
alytic activity. The expected structure of the targeted
TAFI locus was confirmed by Southern blot analysis.
Thus, after SacI digestion of genomic DNA, the probe
that encompasses exon 6 recognized a band of approx-
imately 9.2 kb in the wild-type allele and a band of
approximately 7.0 kb in the disrupted allele (Figure
1b). Germline transmission of the TAFI-null allele was
achieved in a number of chimeric mice derived from
two independent embryonic stem cell clones. Mice
generated from both embryonic stem cell clones were
characterized independently and were shown to be
indistinguishable phenotypically. Consequently,
most of the work described in the current study was
performed with one line.
The targeted disruption of the TAFI gene resulted
in the truncation of the TAFI transcript as shown by
RT-PCR of mRNA isolated from the liver of homozy-
gous TAFI-null mice (Figure 1d). The liver was the
main tissue in which TAFI mRNA was detected by
Northern blot analysis in the mouse (42, 43). Using
primers that correspond to the 5′ and 3′ end of TAFI
cDNA, the RT-PCR produced a fragment of approx-
imately 1,000 bp in TAFI-deficient mice compared
with a fragment of approximately 1,350 bp in the
wild-type littermates. The RT-PCR amplified both
fragments when mRNA from heterozygous litter-
mates was tested. In the absence of reverse transcriptase,
no products were obtained.
To determine if the truncated TAFI transcript in the
homozygous null mice leads to a synthesis of a truncat-
ed TAFI protein, Western blot analysis of plasma samples
from different genotypes was performed. Polyclonal Ab’s
raised against a TAFI peptide corresponding to a region
in the TAFI molecule that is encoded by exon 5 was used
(Figure 1c). Therefore, if a truncated form of TAFI pro-
tein existed in circulation, it should be detected using this
Ab. In the plasma from the wild-type and heterozygous
TAFI mice, polyclonal Ab’s bound to a band with a
molecular weight slightly higher than that of albumin.
This is consistent with the predicted molecular weight for
mouse TAFI. On the other hand, no band was detected in
the plasma from TAFI-deficient mice. The lack of TAFI
protein in the plasma of TAFI-deficient mice was also
demonstrated using a commercially available ELISA kit
for detection of human TAFI, with purified human TAFI
as standard. The plasma level of TAFI in heterozygous
mice was found to be about half of that detected in the
wild-type mice (Table 1). Only the background value in
the ELISA was found with plasma samples from homozy-
gous mice, which was similar to the value obtained with
human plasma samples depleted of TAFI.
Viability and fertility of TAFI-deficient mice. DNA analysis
of 259 progeny derived from TAFI+/– intercrosses
showed that TAFI mice were born in the expected
Mendelian ratio of one TAFI+/+/two TAFI+/–/one TAFI–/–
(Table 2). This indicated that TAFI deficiency did not
lead to embryonic lethality. TAFI-deficient mice devel-
oped normally and reached adulthood. No physical
abnormalities were observed in these mice up to 24
months of age. Matings of homozygous males with
homozygous females produced viable offspring of nor-
mal litter size at normal frequency indicating that TAFI-
deficient mice were fertile and pregnancies were carried
to full term. Hematological analysis of TAFI–/– mice did
not show any major differences in blood cell counts,
plasma fibrinogen level, PT, and aPTT, compared with
those of TAFI+/+ mice (Table 3). There was no abnor-
mality in liver and kidney functions as shown by blood
chemistry analysis (Table 3).
The Journal of Clinical Investigation | January 2002 | Volume 109 | Number 1 105
Table 2
F2 offspring of TAFI+/– matings 
GenotypeA TAFI+/+ TAFI+/– TAFI–/–
Number of pups 64 127 68
Percentage of total 25% 49% 26%
AGenotype of offspring from intercrossing of heterozygous TAFI mice was
determined by PCR.
Table 3
Hematological and hemostasis analysis 
TAFI+/+ TAFI–/–
Hemoglobin (g/%) 14.7 ± 1.4 (n = 15) 14.5 ± 1.2 (n = 15)
Platelet count (109/l) 1013 ± 176 (n = 15) 1053 ± 288 (n = 15)
Fibrinogen (%) 100 ± 35 (n = 15) 96 ± 26 (n = 15)
Alkaline phosphatase (IU/l) 85.4 ± 22 (n = 5) 87.5 ± 20 (n = 4)
Blood urea nitrogen (mg/dl) 25.8 ± 4.7 (n = 5) 24.3 ± 5.8 (n = 4)
Creatine (mg/dl) 0.44 ± 0.06(n = 5) 0.5 ± 0.08 (n = 4)
PT (s) 10.9 ± 0.41 (n = 6) 11.3 ± 0.38 (n = 6)
aPTT (s) 19.3 ± 0.97 (n = 6) 20.0 ± 0.83 (n = 6)
For blood chemistry analysis, serum was obtained from clotted whole blood and
analyzed by IDEXX Veterinary Services Inc. Fibrinogen level was measured accord-
ing to the method described by Macart (38). The aPTT and PT were performed
with platelet-poor plasma using a MLA Electra 900C coagulometer. The number
of mice used in each group is indicated in parentheses.
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TAFI-deficient mice did not suffer from any apparent
untoward effects of tail transection when samples were
taken for genotyping. To evaluate the effect of TAFI defi-
ciency on hemostasis, blood loss was determined during
the 30 minutes following tail transection of a 1-mm seg-
ment. The mice used in the study had intact tails prior
to the amputation because routine genotyping was per-
formed with ear biopsies instead of tail clips. There was
no statistically significant difference in the amount of
blood loss between TAFI-deficient mice and the control
mice (Figure 2a). It has been shown that the 129/Sv mice
have significantly longer bleeding times than the
C57Bl/6 mice do, indicating that genetic backgrounds
influence hemostasis (44). In
this study, we compared off-
spring of TAFI-deficient mice
with offspring of their wild-
type littermates, rather than
comparing among the same
littermates. However, the pres-
ent results were similar to
those obtained from our previ-
ous study in which tail-bleed-
ing time in TAFI-deficient
mice was compared with their
littermate controls and no dif-
ferences were found (44). The
effect of TAFI deficiency on
bleeding was also studied in
the presence of an antithrom-
botic agent that promoted
exaggerated bleeding. In the
presence of low-molecular-
weight heparin, there were
wide individual differences in
the extent of bleeding. However, the blood loss in TAFI-
deficient mice was not significantly different from that
in the wild-type mice, implying that TAFI deficiency did
not compromise hemostasis severely (Figure 2b).
Effect of TAFI deficiency on plasma carboxypeptidase activ-
ity and in vitro clot lysis. To demonstrate a role of acti-
vated TAFI in fibrinolysis, the effect of TAFI deficien-
cy was tested in a plasma clot lysis assay. Coagulation
and fibrinolysis were initiated in mouse platelet-poor
plasma with thrombin and t-PA, respectively. In the
presence of 50 nM thrombomodulin, clot lysis time
was prolonged at least twofold in plasma from wild-
type mice (Figure 3a). This thrombomodulin-depend-
ent prolongation was likely due to the activation of
TAFI by a thrombin-thrombomodulin complex since
an inhibitor of CPI reversed it (data not shown). A sim-
ilar extent of prolongation was observed in plasma
from heterozygous mice, indicating that while their
plasma TAFI antigen level is about half of that in wild-
type, enough TAFI is activated to perturb fibrinolysis.
There was no prolongation of clot lysis time in plasma
from TAFI-deficient mice upon the addition of throm-
bomodulin (Figure 3b). On the other hand, an addi-
tion of purified human TAFI to the same plasma
resulted in a similar prolongation of clot lysis time as
seen with plasma from the wild-type and heterozygous
mice (data not shown). Therefore, activated TAFI is
responsible for the retardation of fibrinolysis in the
wild-type and heterozygous mice. These results are in
agreement with TAFIa activity measured directly in
these plasma samples with a small molecule substrate,
FA-Ala-Arg, following in vitro activation with a throm-
bin/thrombomodulin complex (Table 1). Further-
more, it was evident that the activity of the second
basic carboxypeptidase in plasma, CPN, remained rel-
atively constant in the three groups of mice and that it
did not influence fibrinolysis.
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Figure 2
Tail bleeding. Wild-type mice and TAFI-deficient mice were anes-
thetized with an intraperitoneal injection of pentobarbital and a 
1-mm segment was amputated from the tip of the tail, as described
in Methods. The tail was immediately immersed in saline at 37°C. The
amount of red blood cells released from the tail wound into saline was
determined with a Baker 9120+CP Cell Counter (a). For tail bleeding
in the presence of low-molecular-weight heparin, mice were injected
with Lovenox (3 mg/kg body weight) in the tail vein 2 minutes before
tail transection, and the amount of blood loss was measured similar-
ly (b). The number of animals used in each group is indicated in
parentheses. RBC, red blood cell; WT, wild-type; KO, knockout.
Figure 3
Plasma clot lysis profile. (a) represents wild-type mice and (b) represents TAFI-deficient mice. Clot
formation and lysis were initiated in the recalcified (Ca2+, 17 mM) mouse plasma with human throm-
bin (2.5 NIH U/ml) and t-PA (0.017 µg/ml), respectively. TM, human recombinant soluble throm-
bomodulin, was added at a final concentration of 50 nM to enhance activation of endogenous TAFI.
Absorbance at 405 nm was plotted against incubation time. Typical clot lysis profile obtained in the
absence of TM and t-PA (solid line with open circle), in the absence of TM but presence of t-PA (dot-
ted line with filled circle), in the presence of TM but absence of t-PA (dashed line with filled square),
and in the presence of both TM and t-PA (dashed line with open square) is shown. 
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Thrombosis models in TAFI-deficient mice. To investigate
the effect of TAFI deficiency on the development of
arterial thrombosis, TAFI-deficient mice and their
wild-type littermates were subjected to a photochemi-
cal injury in the carotid artery and blood flow was
monitored continuously. Mean time for an occlusive
thrombus to form in TAFI-deficient mice was 59.2 ± 5.2
minutes (n = 15) compared with 59.1 ± 6.3 minutes in
TAFI +/+ mice (n = 14), indicating that TAFI deficiency
did not influence the rate of acute thrombus formation
significantly in this arterial thrombosis model. The
effect of TAFI deficiency was also tested on venous
thrombosis. Mean time for an occlusive thrombus for-
mation was 55.8 ± 43.8 minutes (n = 4) in TAFI-defi-
cient mice, and it was 81.8 ± 41.4 minutes (n = 6) in
wild-type littermates. TAFI deficiency had no signifi-
cant impact on the rate of venous thrombosis.
The potential involvement of TAFI in endogenous
fibrinolysis was further examined in the thrombin-
induced acute thromboembolism, XCP-induced
thrombosis, and endotoxin-induced disseminated
intravascular coagulation models. In the acute throm-
boembolism model, intravenous injection of thrombin
into conscious TAFI+/+ mice resulted in death within 10
minutes in a dose-dependent manner (Table 4). There
was no major difference in the survival rate between
TAFI+/+ and TAFI–/– mice. While a high dose of throm-
bin activates TAFI in vitro, it is not known if TAFI is
activated following thrombin injection in vivo in this
acute thrombosis model. Thus, TAFI-deficient mice
were challenged with either endotoxin or XCP in
chronic models. Sato et al. demonstrated previously
that LPS injection caused activation of TAFI as well as
induction of hepatic TAFI mRNA in mice (43). Follow-
ing LPS injection (either 30 mg/kg or 40mg/kg), the
survival rates were similar between TAFI-deficient and
the wild-type mice (Figure 4). Because of reports on
transient fibrin deposition in the kidney of mice inject-
ed with LPS (34, 45), in the separate experiments kid-
neys from animals injected with either a sublethal dose
(2 mg/kg) or a lethal dose (30 mg/kg) of LPS 3 hours
earlier were stained for fibrin. While there was some
specific fibrin staining within the glomeruli of both the
wild-type and TAFI-deficient littermates following LPS
injection, there was no significant difference in the
extent of staining between the two groups (data not
shown). In XCP-challenged subacute coagulation
model, the significant decreases in the plasma fibrino-
gen level and platelet counts observed at 2 hours and
16 hours after the stimulus were similar in both geno-
types (Table 5). Furthermore, the survival rate did not
differ between the two groups.
Kaolin-induced writhing test. Since it has been shown
that TAFI cleaves C-terminal arginine residue from
bradykinin in vitro (12, 17, 18), the effect of TAFI defi-
ciency on the writhing reaction induced by kaolin was
studied in normal animals. The number of mice
writhing during 15 minutes after the intraperitoneal
injection of kaolin was 1.29 ± 1.78 (n = 14) in the wild-
type compared with 1.21 ± 1.85 (n = 14) in TAFI-defi-
cient mice. Kaolin is a known activator of factor XII
and induces formation of bradykinin, which in turn
induces writhing response. The result with TAFI-defi-
cient mice demonstrated that TAFI does not play a
major role in the degradation of bradykinin under nor-
mal conditions in this model.
Discussion
A correlation between fibrinolytic potential and the
plasma level of TAFI antigen has been documented in
the general population (46). In normal healthy subjects,
plasma TAFI antigen level varies between 45% and 150%
of the mean value (46–49). There are some reports that
age influences the TAFI antigen level (47–49). The pres-
ence of polymorphisms in the TAFI gene has been
observed (50–53), and it is now known that some of the
polymorphisms are responsible for variations in the
plasma TAFI antigen level (52, 53). The gene encoding
human TAFI has been mapped to chromosome
13q14.11 (54, 55), but no known hemostatic disease is
currently associated with this region; there has been no
report of an individual lacking in plasma TAFI. One
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Table 4
Survival rate in thrombin-induced acute pulmonary thromboembolism 
Thrombin dose Survival rate Survival rate 
in TAFI+/+ (%) in TAFI–/– (%)
1,600 NIH U/kg 87 (n = 8) 62 (n = 8)
2,400 NIH U/kg 78 (n = 9) 64 (n = 11)
3,200 NIH U/kg 60 (n = 15) 50 (n = 12)
Human thrombin was injected intravenously over 2 to 3 seconds into the tail
vein of conscious mice. The survival rate at 10 minutes after thrombin admin-
istration was taken as an index of the severity of pulmonary thromboembolism.
The number of mice used in each group is indicated in parentheses.
Figure 4
Effect of endotoxin on the survival of wild-type and TAFI-deficient
mice. Mice were injected intraperitoneally with endotoxin (either 30
mg/kg or 40 mg/kg body weight) dissolved in saline. The mice were
observed daily for signs of endotoxemia, and survival time was
recorded. Survival curve for wild-type mice injected with 30 mg/kg
body weight (solid line with filled circle), with 40 mg/kg (dotted line
with filled circle), TAFI-deficient mice injected with 30 mg/ kg (solid
line with open square), and with 40 mg/kg (dotted line with open
square) is shown. The number of animals used in each group is indi-
cated in parentheses.
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study indicated an increased TAFI level was a mild risk
factor for venous thrombosis (49). On the other hand,
surprisingly, there has been a recent report that indi-
cated lower levels of plasma TAFI as a risk factor for
coronary heart diseases (56). Thus, we generated and
characterized TAFI-deficient mice to study its patho-
physiological role in various thrombotic diseases in the
light of these current conflicting reports.
Mice deficient in TAFI were born without any
abnormalities and developed normally to reach adult-
hood. They were fertile, producing viable offspring,
which showed that TAFI deficiency was compatible
with embryogenesis and development. Hematological
and hemostatic analysis revealed no major differences
between TAFI-deficient and wild-type mice, including
tail bleeding. Previously, it was shown that in vitro
clots formed from patient plasma deficient in coagu-
lation factor VIII, IX, X, or XI lysed prematurely when
induced by exogenous t-PA (36). When TAFI was acti-
vated upon addition of either the missing coagulation
factor or thrombomodulin to such plasma, normal
lysis was restored. Such data implicated a physiologi-
cal role of TAFI in stabilization of newly formed fib-
rin clots. However, the results of tail bleeding in this
study demonstrated that loss of TAFI did not lead to
grossly impaired hemostasis.
The effect of TAFI deficiency was also studied in arte-
rial as well as venous thrombosis models induced by a
photochemical injury. In these models, initial forma-
tion of an occlusive thrombus depends on the balance
between coagulation and fibrinolysis. TAFI deficiency
did not have a significant impact on the rate of throm-
bus formation in either vessel. To test the possibility
that enhanced endogenous fibrinolysis due to the
absence of activated TAFI may facilitate spontaneous
lysis of the stabilized clot, animals were allowed to
recover, and the size of the residual thrombus was
measured 24 hours later. We did not observe any sta-
tistically significant difference in the cross-sectional
area of the thrombus from TAFI-deficient mice com-
pared with that of the wild-type littermates (data not
shown). Such results indicate that TAFI does not great-
ly influence the rate of spontaneous reperfusion. It is
possible that PAI-1 release from the vessel wall in
response to a photochemical injury may well mask any
effect of TAFI. In the same arterial model, PAI-1 has
been shown to affect both occlusion and spontaneous
reperfusion rate (57, 58).
TAFI-deficient mice were challenged with other stim-
uli that are known to induce systemic intravascular
coagulation. In a pulmonary thromboembolism model
reported previously, intravenous injection of human
thrombin into mice caused quick death (59–61). Fibrin
deposition was detected in both large and small vessels
in the lung (59, 61). In one of the papers, the authors
demonstrated that thrombin-induced feedback activa-
tion of clotting factors, and subsequent additional for-
mation of thrombin, and hence fibrin formation, 
contributed significantly to organ failures (61). Fur-
thermore, it was proposed that thrombin-induced acti-
vation of factor XIII and/or TAFI, which render newly
formed fibrin clots more resistant to plasmin degrada-
tion, as additional pathological mechanisms. In our
study, survival rate determined at 10 minutes after
thrombin injection was similar among TAFI-deficient
mice compared with the wild-type. To investigate any
subtle effect of TAFI deficiency in response to throm-
bin injection, tissue fibrin deposition was measured
using 125I-labeled human fibrinogen in separate exper-
iments. There was no significant accumulation of
radioactivity in the lung and kidney of the control mice
at any time point up to 6 hours after thrombin injec-
tion (our unpublished observations). Intravenous injec-
tion of thrombin does not lead to substantial accumu-
lation of fibrin in the kidney or lung in mice.
Following endotoxin or XCP injection, there were no
differences in the survival rate between the wild-type
mice and TAFI-deficient mice. Yamamoto and Loskut-
off showed that LPS-induced transient fibrin deposi-
tion in tissue-specific vasculature was likely due to
activation of the coagulation cascade through induc-
tion of tissue factor expression, and concomitant sup-
pression of the fibrinolytic system through increased
PAI-1 and decreased urokinase-type tissue plasmino-
gen activator (45). In numerous studies, agents that
directly inhibit tissue factor or thrombin as well as
agents that inhibit amplification of coagulation cas-
cade such as activated protein C have been effective in
reducing endotoxin-induced lethality (for review, see
refs. 62, 63). On the other hand, the effectiveness of an
enhanced endogenous fibrinolytic system against a
lethal dose of LPS has not been reported. However,
reduced renal fibrin deposition in response to a non-
lethal dose of endotoxin has been demonstrated in 
α2-antiplasmin–deficient mice (34, 64), but not in PAI-
1–deficient mice (64). In the current study, we did not
detect any difference in the extent of fibrin deposition
in the kidney of wild-type and their TAFI-deficient lit-
termates in response to LPS.
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Table 5
Survival rate, fibrinogen level, and platelet counts following XCP
challenge
TAFI+/+ (n = 15) TAFI–/– (n = 15)
Survival rate (%)
at 2 hours 93 87
at 16 hours 53 60
Plasma fibrinogen level (%)
at 0 hours 100 ± 35 96 ± 26
at 2 hours 52 ± 23 56 ± 16
at 16 hours 83 ± 34 106 ± 56
Platelet counts (109/l)
at 0 hours 1013 ± 176 1053 ± 288
at 2 hours 328 ± 252 416 ± 239
at 16 hours 319 ± 285 353 ± 142
Mice were injected intraperitoneally with 150 µg/kg body weight factor X
coagulant protein from Russell viper venom. The survival rate, fibrinogen level,
and platelet counts were determined 2 and 16 hours later. The number of mice
used in each groups is indicated in parentheses.
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A potential involvement of TAFI in degradation of
bradykinin was tested in TAFI-deficient mice using the
kaolin-induced writhing model. Previous work has
shown that kaolin induced writhing responses by way of
bradykinin formation and that inhibition of the degra-
dation of bradykinin by pretreatment of mice with a
nonselective inhibitor of basic carboxypeptidases poten-
tiated the writhing response in this model (40, 41). In the
absence of circulating TAFI antigen, however, there was
no potentiation of the writhing response, indicating that
TAFI does not contribute significantly to the degrada-
tion of bradykinin under normal conditions.
In summary, we have generated and characterized
TAFI-deficient mice. The current study demonstrated
that TAFI deficiency is compatible with murine life.
TAFI-deficient mice did not exhibit any abnormal phe-
notypes including hemostasis. Furthermore, the dis-
ruption of TAFI gene did not appear to participate in
the acute challenges tested here. While it is evident
from previous studies using TAFI inhibitors that TAFI
plays a regulatory role in t-PA–induced thrombolysis
(23–26), its effect on endogenous fibrinolysis may be
more subtle. Our study also indicated that TAFI does
not play a significant role in bradykinin turnover under
normal conditions. Any potential role(s) of TAFI in the
degradation of other biologically active peptides, espe-
cially anaphylatoxins, can now be tested unequivocally
in TAFI-deficient mice instead of using nonselective
inhibitors of basic carboxypeptidases. Currently, stud-
ies are underway to address these issues. During the
preparation of our manuscript, Wagenaar et al. inde-
pendently reported generation of TAFI-deficient mice
and observed a lack of abnormal phenotypes in their
TAFI-deficient mice, consistent with our result (65).
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